News
TMBMKGB-05Y | A complete U.K. 5 Year Gilt bond overview by MarketWatch. View the latest bond prices, bond market news and bond rates.
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback